Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29896173 | 1.00 | PIK3CA (0.43) | PIK3CAROCK2GAASOSTTLR2 | |
| SCHEMBL27188830 | 0.89 | ROCK2 (0.41) | ROCK2GAASCN2ASCN10ANAMPT | |
| SCHEMBL29896091 | 0.89 | ROCK2 (0.41) | ROCK2GAASCN2ASCN10ANAMPT | |
| SCHEMBL29896176 | 0.88 | PIK3CA (0.42) | PIK3CAROCK2GAASOSTSCN2A | |
| SCHEMBL27188849 | 0.88 | PIK3CA (0.42) | PIK3CAROCK2GAASOSTSCN2A | |
| SCHEMBL27188837 | 0.88 | GAA (0.41) | ROCK2GAAEPHX2 | |
| SCHEMBL29896103 | 0.88 | GAA (0.41) | ROCK2GAAEPHX2 | |
| SCHEMBL27188804 | 0.88 | PIK3CA (0.45) | PIK3CAROCK2SOSTTLR2 | |
| SCHEMBL29896169 | 0.88 | PIK3CA (0.45) | PIK3CAROCK2SOSTTLR2 | |
| SCHEMBL29896088 | 0.88 | POLB (0.44) | ROCK2EPHX2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | claimed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
| EP-4034257-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | PIK3CA 3041/4885ROCK2 4595/4885GAA 3884/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | PIK3CA 3041/4885ROCK2 4595/4885GAA 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.